Clinical trials: Dose Finding Study
Rhinitis, Allergic, Perennial
A Study of Mometasone Furoate Nasal Spray in Perennial Allergic Rhinitis (Study P03748)(COMPLETED)
This is a multicenter, randomized, double-blind within the dose level, parallel group comparison of mometasone furoate nasal spray in subjects with perennial allergic rhinitis to examine the minimal effective dose, the…
- Trial name
- NCT00779545
- Testing
- Mometasone furoate
- Volunteers
- 455 people
- Sponsor
- Organon and Co
Osteoarthritis of the Knee
Dose Finding Study of Bone Morphogenetic Protein 7 (BMP-7) in Subjects With Osteoarthritis (OA) of the Knee
The objectives of the study are to evaluate the safety and efficacy of intraarticular BMP-7 for the treatment of osteoarthritis of the knee.
- Trial name
- NCT01111045
- Testing
- Bone morphogenetic protein 7
- Where
- 25 sites in United States
- Volunteers
- 355 people
- Sponsor
- Stryker Biotech
Cancer
A Dose-Finding Study of E7050 Administered Orally to Patients With Advanced Solid Tumors
The purpose of this study is to determine the maximum tolerated dose (MTD) of E7050 given orally in patients with advanced solid tumors.
- Trial name
- NCT00869895
- Testing
- E7050
- Where
- 2 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Eisai Inc.
Non-small Cell Lung Cancer, Melanoma
IMM60 and Pembrolizumab in Melanoma and NSCLC
The goal of this clinical trial is to learn about IMM60 with or without pembrolizumab in participants with advanced melanoma or non-small cell lung cancer.
- Trial name
- NCT05709821
- Testing
- IMM60, Pembrolizumab
- Where
- 14 sites in United States, Spain and 1 more
- Volunteers
- 1 people
- Sponsor
- iOx Therapeutics
Chronic Obstructive Pulmonary Disease
Confirmatory Dose Finding Study of 2 Dosages of CHF 4226 pMDI (Carmoterol) in Patients With COPD
The purpose of this study is to confirm the dose of CHF 4226 (carmoterol) that should be given once a day to patients with COPD in order for the effect to last for 24 hours.
- Trial name
- NCT00640484
- Testing
- carmoterol (CHF 4226), salmeterol
- Where
- 15 sites in United States
- Volunteers
- 57 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Prostate Cancer
A Study to Evaluate the Safety, Tolerability and Efficacy of a Liproca® Depot Injection in Patients With Prostate Cancer
A Single Blind, Two-Stage Dose Finding Study to Evaluate the Safety, Tolerability and Efficacy of a Single Liproca® Depot Injection into the Prostate in Patients with Localized Prostate Cancer,Assigned to Active Surveillance who…
- Trial name
- NCT03348527
- Testing
- 2-Hydroxyflutamide Depot
- Where
- 10 sites in Canada, Finland and 1 more
- Volunteers
- 61 people
- Sponsor
- Lidds AB
Glioblastoma Multiforme
Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme
This is an open-label, dose finding, multiple-dose study in subjects with recurring/relapsing glioblastoma multiforme. Three dose levels of MPC-6827 will be administered with carboplatin to three separate cohorts.
- Trial name
- NCT00635557
- Testing
- MPC-6827 + Carboplatin
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Myrexis Inc.
Gout and Hyperuricemia
Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia
This study is to examine the hypothesis that administration of RDEA3170 to Japanese patients with gout or asymptomatic hyperuricemia in doses of 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg once daily, respectively will result in…
- Trial name
- NCT02078219
- Testing
- RDEA3170, Allopurinol
- Where
- 14 sites in Japan
- Volunteers
- 204 people
- Sponsor
- AstraZeneca
Advanced Solid Tumor, Breast Cancer
Combination Therapy of F16IL2 and Doxorubicin in Solid Tumour Patients
This Phase Ib/II study is an openlabel, multicenter study for patients with solid tumors and breast cancer amenable to anthracyclin therapy.
- Trial name
- NCT01131364
- Testing
- F16IL2 in combination with doxorubicin
- Where
- 5 sites in Italy
- Volunteers
- 29 people
- Sponsor
- Philogen S.p.A.
Obesity
A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight
This study is open to adults, aged 18 to 75 years, with overweight or obesity. People with body mass index (BMI) of 27 or higher to join the study. People who have diabetes cannot participate.
- Trial name
- NCT04667377
- Testing
- BI 456906
- Where
- 43 sites in United States, Australia and 10 more
- Volunteers
- 387 people
- Sponsor
- Boehringer Ingelheim
Pain, Postoperative
Study to Find Out the Optimal Dose of Caffeine in the Combination Tablet of Naproxen Sodium and Caffeine in Patients Experiencing Moderate to Severe Pain After Having Wisdom Teeth Removed
The researchers in this study wanted to find out the optimal dose of Caffeine in the combination tablet of Naproxen Sodium and Caffeine that works in patients experiencing moderate to severe pain after having wisdom teeth…
- Trial name
- NCT04132336
- Testing
- Naproxen sodium/Caffeine (BAY2880376), Naproxen sodium (Aleve), Caffeine
- Where
- United States
- Volunteers
- 193 people
- Sponsor
- Bayer
Cancer
A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)
This is a first in human study to identify whether FP-1305 is suitable to use in humans. The previous pre-clinical studies have demonstrated that FP-1305 binds to a receptor known as CLEVER-1.
- Trial name
- NCT03733990
- Testing
- FP-1305 (bexmarilimab)
- Where
- 11 sites in United States, Finland and 4 more
- Volunteers
- 216 people
- Sponsor
- Faron Pharmaceuticals Ltd
Enterovirus Infections
A Study to Evaluate the Immunogenicity and Safety of EV71 Vaccine in Pediatric Subjects
The objectives of this study are to evaluate the immune response and safety profiles of two injections of EV71 vaccine administrated with or without adjuvant Al(OH)3 at 0.5-μg and 1-μg dose in children aged 3 to 6 years old and 2…
- Trial name
- NCT03268083
- Testing
- EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AI(OH)3] per dose), EV71 vaccine ([1 μg total protein + adjuvant 150 μg AI(OH)3] per dose), EV71 vaccine ([1 μg total protein ] per dose)
- Where
- 4 sites in Taiwan
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Enimmune Corporation
Heart Failure
A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure
This was a multicenter, randomized, placebo- and active-controlled, parallel-group, 24-week trial to investigate the efficacy, safety, and tolerability of XXB750 in participants with HFrEF/HFmrEF.
- Trial name
- NCT06142383
- Testing
- XXB750 Low dose, XXB750 Medium Dose, XXB750 High Dose
- Where
- 62 sites in United States, Bulgaria and 10 more
- Volunteers
- 136 people
- Sponsor
- Novartis Pharmaceuticals
Dry Eye Disease (DED)
Dose-Finding Study of HUC1-394 in Participants With Dry Eye Disease
Clinical trial aims to determine the optimal dosing regimen by evaluating the efficacy and safety of HUC1-394 across different dosing frequencies in patients with moderate to severe dry eye disease.
- Trial name
- NCT07656688
- Testing
- HUC1-394
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Huons Co., Ltd.
Grass Pollen Allergy
Safety and Dose Finding Trial of BM32 in Subjects Suffering From Grass Pollen Allergy
The study will evaluate the dose response of immunotherapy against grass pollen allergy using the recombinant grass pollen vaccine BM32.
- Trial name
- NCT01445002
- Testing
- BM32
- Where
- Austria
- Volunteers
- 79 people
- Sponsor
- Biomay AG
GERD With Erosive Esophagitis
A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients With Erosive Esophagitis.
The primary objective is to compare the efficacy between three doses of AZD0865 (25, 50 and 75 mg). The secondary objectives are to compare the efficacy between the three doses of AZD0865 and esomeprazole 40 mg and to evaluate…
- Trial name
- NCT00206245
- Testing
- AZD0865
- Where
- 202 sites in United States, Canada and 8 more
- Volunteers
- 1,400 people
- Sponsor
- AstraZeneca
Atrial Fibrillation (AF)
Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.
The purpose of this study is to try to find the best dose of the new drug BAY 2433334 to give to participants and to look at how well BAY 2433334 works in patients with irregular heartbeat (atrial fibrillation) that can lead to…
- Trial name
- PACIFIC-AF (NCT04218266)
- Testing
- BAY2433334, Apixaban
- Where
- 93 sites in Austria, Belgium and 12 more
- Volunteers
- 755 people
- Sponsor
- Bayer
Agitation, Delirium
Study of BXCL501 In Agitation Associated With Delirium in ICU Patients
This study is designed to determine and evaluate the optimal BXCL501 starting dose (StartD) that will safely and effectively reduce agitation associated with delirium in ICU patients.
- Trial name
- NCT05313386
- Testing
- BXCL501
- Where
- United States
- Sponsor
- BioXcel Therapeutics Inc
Helicobacter Pylori, Gastritis
Safety and Immunogenicity of Chiron's Investigational H. Pylori Vaccine in Healthy Adults
This study was designed to investigate the safety and immunogenicity of Chiron's investigational H. pylori (HP3) vaccine
- Conditions
- Helicobacter Pylori, Gastritis, Gastric Cancer, Gastroduodenal Ulcers
- Trial name
- NCT00613665
- Testing
- helicobacter pylori vaccine
- Where
- Germany
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.